Table 5.
Patient outcomes according to the empirical antimicrobial treatment strategy used
| Total | Broad-spectrum antimicrobial group | Narrow-spectrum antimicrobial group | p value | |
|---|---|---|---|---|
| Emergence of new MDR pathogensa | 23 (9.1%) | 19 (11.9%) | 4 (4.2%) | 0.042 |
| Clinical cure on day 7 | 135 (53.1%) | 88 (55.3%) | 47 (49.5%) | 0.436 |
| ICU mortalitya | 18 (7.1%) | 14 (8.8%) | 4 (4.2%) | 0.211 |
| 28-day mortality (n = 253) | 31 (12.3%) | 23 (14.6%) | 8 (8.4%) | 0.170 |
| Number of days in the ICU (N = 236)a, b | 7 (4–15) | 7 (4–15) | 7 (3–16) | 0.707 |
| On vasoactive drugs | 2 (0–5) | 3 (1–6) | 1 (0–5) | 0.001 |
| On Invasive mechanical ventilation | 3 (0–8) | 4 (0–9) | 2 (0–5) | 0.015 |
| Receiving renal replacement therapy | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.026 |
| ICU-free days (N = 221)a, c | 21 (11–24) | 21 (10–24) | 21 (11–25) | 0.529 |
| Hospital-free days (N = 221)a, c | 0 (0–9) | 0 (0–3) | 0 (0–15) | 0.013 |
| Antimicrobial-free days (N = 221)a, c | 14 (5–20) | 13 (3–18) | 17 (8–21) | 0.001 |
| Infection relapsea | 14 (5.6%) | 7 (4.5%) | 7 (7.4%) | 0.398 |
Results are shown as n (%) or median (IQR) where applicable
aMeasured from day 2 or later during the 28-day follow-up period and not present before day 2
bIn the subgroup of intensive care unit (ICU) survivors
cIn the subgroup of patients alive at day 28